Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation

Xueyan Cao,Yang Yang,Wei Zhou,Yue Wang,Xue Wang,Xianxiu Ge,Fei Wang,Fangfang Zhou,Xueting Deng,Lin Miao
DOI: https://doi.org/10.1186/s12885-023-10954-8
IF: 4.638
2023-05-24
BMC Cancer
Abstract:Aprepitant, as a neurokinin-1 receptor (NK-1R) antagonist, originally applied for curing chemotherapy-induced nausea and vomiting, has been reported to have significant antitumor effect on several malignant tumors. However, the effect of aprepitant on gallbladder cancer (GBC) is not clear yet. This study aimed to investigate the anti-tumor activity of aprepitant on GBC and the potential mechanisms.
oncology
What problem does this paper attempt to address?